Drug firm Zydus Cadila on August 13 stated it has established Remdesivir under the brand name Remdac, used to treat patients experiencing severe signs of COVID-19, in the Indian market. Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.

The business said the drug will be made accessible across India throughout the group's strong distribution chain reaching out to private and government hospitals treating COVID-19 patients.

"Remdac is the most inexpensive drug as we'd love to allow patients to gain access to this critical drug in treating COVID-19," Cadila Healthcare Managing Director Dr Sharvil Patel stated.

Through the course of this outbreak, the organization's efforts have been focused on supporting individuals in this health crisis, whether it is through creating vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests offered or exploring new treatment choices, Patel added.

In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational medication, which has been issued an emergency usage authorisation from the US Food and Drug Administration (USFDA) to treat patients experiencing acute signs of COVID-19.

The active pharmaceutical ingredient (API) for your drug was developed and manufactured at the team's API manufacturing centers in Gujarat.

Zydus Cadila's vaccine candidate ZyCov-D is now in phase II of their clinical trials.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 387 apiece on BSE, 0.44 percent higher contrary to their previous closure.